Idiopathic pulmonary fibrosis: early detection and referral
- PMID: 24746629
- PMCID: PMC4785031
- DOI: 10.1016/j.rmed.2014.03.008
Idiopathic pulmonary fibrosis: early detection and referral
Abstract
Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3-5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Vigilance among clinicians in recognizing IPF early in the disease course remains critical to properly caring for these patients, as this provides the widest range of management options. When IPF is suspected, a multidisciplinary evaluation (MDE) by a clinician, radiologist and pathologist with ILD expertise should occur, as this improves diagnostic agreement in both community and academic settings. When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center should be considered. ILD center referral may also provide access specialized care, including clinical trials and lung transplantation, and should be considered for any patient with an established diagnosis of IPF.
Keywords: ILD; IPF; Lung transplant; Pulmonary fibrosis.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Dr. Noth has received honoraria for advisory boards with Boehringer Ingelheim, InterMune, Anthera within the last 12 months related to IPF. He has also received speaking honoraria from GSK and receives consulting fees for Immuneworks. He also has study contracts with the NIH, Stromedix, Sanofi, and Boehringer Ingelheim for the conduct of clinical trials in IPF. Boehringer Ingelheim Pharmaceuticals, Inc. paid the processing charge for this article and was allowed to review the manuscript for factual accuracy with no editorial input.
Figures
References
-
- King TE., Jr Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005;172:268–279. - PubMed
-
- American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. - PubMed
-
- Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199–203. - PubMed
-
- De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J. 2001;17:954–961. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
